• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Grappling Covishield fear in India: the urgent need for strong countermeasures to build vaccine confidence.

作者信息

Poddar Abhijit, Rao S R

机构信息

Centre for Bio-Policy Research (CBPR), MGM Advanced Research Institute (MGMARI), Sri Balaji Vidyapeeth (Deemed-to-be-University), Pondicherry, India.

Sri Balaji Vidyapeeth (Deemed-to-be-University), Pondicherry, India.

出版信息

Lancet Reg Health Southeast Asia. 2024 Jul 11;27:100447. doi: 10.1016/j.lansea.2024.100447. eCollection 2024 Aug.

DOI:10.1016/j.lansea.2024.100447
PMID:39071894
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11283219/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6852/11283219/1d869f853665/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6852/11283219/1d869f853665/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6852/11283219/1d869f853665/gr1.jpg

相似文献

1
Grappling Covishield fear in India: the urgent need for strong countermeasures to build vaccine confidence.应对印度对科维希德疫苗的恐惧：迫切需要采取有力对策以建立疫苗信心。
Lancet Reg Health Southeast Asia. 2024 Jul 11;27:100447. doi: 10.1016/j.lansea.2024.100447. eCollection 2024 Aug.
2
ADR Profile of the Covishield Vaccine Among Healthcare Workers in a Tertiary Care Teaching Hospital in India.印度一家三级教学医院医护人员中 Covishield 疫苗的不良药物反应概况。
Curr Drug Saf. 2022;17(4):344-349. doi: 10.2174/1574886317666220113101815.
3
Association between Covishield vaccine and menstrual disturbance. Findings from a cross-sectional study among participants of Zero TB cohort in India.Covishield 疫苗与月经紊乱之间的关联。来自印度 Zero TB 队列参与者的横断面研究结果。
Vaccine. 2024 Jun 11;42(16):3572-3577. doi: 10.1016/j.vaccine.2024.04.063. Epub 2024 Apr 27.
4
Surveillance on Adverse Events Following COVISHIELD (ChAdOx1 nCoV-19) vaccination in Goa, India: An Observational Study.印度果阿州科维希尔德（ChAdOx1 nCoV-19）疫苗接种后不良事件监测：一项观察性研究。
Curr Drug Saf. 2023;18(4):516-527. doi: 10.2174/1574886317666220803104438.
5
Effectiveness of the ChAdOx1 nCoV-19 Coronavirus Vaccine (Covishield) in Preventing SARS-CoV2 Infection, Chennai, Tamil Nadu, India, 2021.2021年，印度泰米尔纳德邦金奈，ChAdOx1 nCoV-19冠状病毒疫苗（Covishield）预防SARS-CoV2感染的有效性
Vaccines (Basel). 2022 Jun 17;10(6):970. doi: 10.3390/vaccines10060970.
6
Effectiveness of BBV152/Covaxin and AZD1222/Covishield vaccines against severe COVID-19 and B.1.617.2/Delta variant in India, 2021: a multi-centric hospital-based case-control study.印度 2021 年 BBV152/Covaxin 和 AZD1222/Covishield 疫苗对严重 COVID-19 和 B.1.617.2/Delta 变异株的有效性：一项多中心医院病例对照研究。
Int J Infect Dis. 2022 Sep;122:693-702. doi: 10.1016/j.ijid.2022.07.033. Epub 2022 Jul 16.
7
Covishield India: demystifying myths through an early multicenter study.印度 Covishield：通过早期多中心研究揭开神话面纱。
Am J Manag Care. 2021 Oct 1;27(10):e339-e342. doi: 10.37765/ajmc.2021.88694.
8
First and second doses of Covishield vaccine provided high level of protection against SARS-CoV-2 infection in highly transmissible settings: results from a prospective cohort of participants residing in congregate facilities in India.科维希尔德疫苗的首剂和第二剂为在高度传染性环境中对 SARS-CoV-2 感染提供了高水平的保护：来自印度聚居设施中居住的参与者的前瞻性队列研究结果。
BMJ Glob Health. 2022 May;7(5). doi: 10.1136/bmjgh-2021-008271.
9
Immunogenicity of two COVID-19 vaccines used in India: An observational cohort study in health care workers from a tertiary care hospital.印度使用的两种 COVID-19 疫苗的免疫原性：来自一家三级保健医院的医护人员的观察性队列研究。
Front Immunol. 2022 Sep 23;13:928501. doi: 10.3389/fimmu.2022.928501. eCollection 2022.
10
Prevalence and determinants of adverse events following ChAdOx1 nCoV-19 vaccination (COVISHIELD) - A retrospective cohort study among healthcare workers in central Karnataka, India.ChAdOx1 nCoV-19疫苗（COVISHIELD）接种后不良事件的患病率及决定因素——印度卡纳塔克邦中部医护人员的一项回顾性队列研究
J Family Med Prim Care. 2023 Nov;12(11):2869-2874. doi: 10.4103/jfmpc.jfmpc_176_23. Epub 2023 Nov 21.

本文引用的文献

1
Persistence of the immune response after two doses of ChAdOx1 nCov-19 (AZD1222): 1 year of follow-up of two randomized controlled trials.两剂 ChAdOx1 nCov-19（AZD1222）后免疫应答的持久性：两项随机对照试验的 1 年随访结果。
Clin Exp Immunol. 2023 Mar 24;211(3):280-287. doi: 10.1093/cei/uxad013.
2
Long COVID: major findings, mechanisms and recommendations.长新冠：主要发现、机制和建议。
Nat Rev Microbiol. 2023 Mar;21(3):133-146. doi: 10.1038/s41579-022-00846-2. Epub 2023 Jan 13.
3
A survey of COVID-19 vaccine acceptance across 23 countries in 2022.
2022年对23个国家新冠疫苗接受情况的调查。
Nat Med. 2023 Feb;29(2):366-375. doi: 10.1038/s41591-022-02185-4. Epub 2023 Jan 9.
4
Fear of Adverse Effects and COVID-19 Vaccine Hesitancy: Recommendations of the Treatment Expectation Expert Group.对不良反应的恐惧与新冠疫苗犹豫：治疗期望专家组的建议
JAMA Health Forum. 2021 Apr 1;2(4):e210804. doi: 10.1001/jamahealthforum.2021.0804.
5
A phase 2/3, participant-blind, observer-blind, randomised, controlled study to assess the safety and immunogenicity of SII-ChAdOx1 nCoV-19 (COVID-19 vaccine) in adults in India.一项2/3期、参与者盲法、观察者盲法、随机对照研究，旨在评估SII-ChAdOx1 nCoV-19（新冠疫苗）在印度成年人中的安全性和免疫原性。
EClinicalMedicine. 2021 Dec;42:101218. doi: 10.1016/j.eclinm.2021.101218. Epub 2021 Nov 30.
6
Predictors of mortality in thrombotic thrombocytopenia after adenoviral COVID-19 vaccination: the FAPIC score.腺病毒 COVID-19 疫苗接种后血栓性血小板减少症的死亡率预测因素：FAPIC 评分。
Eur Heart J. 2021 Oct 14;42(39):4053-4063. doi: 10.1093/eurheartj/ehab592.
7
Thromboembolism and the Oxford-AstraZeneca COVID-19 vaccine: side-effect or coincidence?血栓栓塞与牛津大学-阿斯利康新冠疫苗：副作用还是巧合？
Lancet. 2021 Apr 17;397(10283):1441-1443. doi: 10.1016/S0140-6736(21)00762-5. Epub 2021 Mar 30.
8
Pharmacovigilance in India in Comparison With the USA and European Union: Challenges and Perspectives.印度与美国和欧盟的药物警戒：挑战与展望
Ther Innov Regul Sci. 2019 Nov;53(6):781-786. doi: 10.1177/2168479018812775. Epub 2018 Dec 17.